Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 624 results for "nexium"

Human medicines European public assessment report (EPAR): Ne...

This is a summary of the European public assessment report (EPAR) for Nexium Control. It explains how the European Medicines Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not ... European Medicines Agency, 3 weeks ago
Reporting and Big data Capability Lead PharmaDiversity, 1 month ago

3 images for "nexium"

SearchBug, 3 weeks ago
FDA News, 3 weeks ago
Rocky Mount Telegram, 2 months ago

AstraZeneca Raises Forecast as Nexium Fee Boosts Profit

AstraZeneca Plc (AZN), raised its forecast after reporting quarterly profit that beat analyst estimates, helped by a $200 million payment from one-time suitor Pfizer Inc. for rights to an over-the-counter version of the Nexium heartburn treatment. ...
 BusinessWeek1 month ago

Thales achieves successful testing of NEXIUM Wireless broadband 4G/LTE standard professional mobile radio by EDF users

Thales, a provider of services and solutions for aerospace, defence, transportation and security markets, announced on Wednesday that its NEXIUM Wireless broadband 4G/LTE standard professional mobile radio (PMR) solution has been successfully ...
 Individual.com1 month ago Thales Tests LTE PMR Solution With French Utility (7/2/14)  Radio Resource Magazine1 month ago

Nexium generic next big opportunity for Ranbaxy: Angel

Given the Sun-Ranbaxy merger, Nangra sees an upside potential of 8-10 percent in Ranbaxy.
 Money Control2 months ago Ranbaxy's FDA problems stymie launch of generic Nexium and the relief it would bring to consumers  FiercePharmaManufacturing2 months ago Hold Ranbaxy Labs; target of Rs 615: KRChoksey  Moneycontrol.com2 weeks ago Insurers balk at pricey generic version of ancient GSK heart drug  FiercePharma1 month ago
Silicon India

USFDA boost for Ranbaxy; see akin deal for Nexium: Dandekar

After a long stretch of regulatory hassles, Vikas Dandekar of PharmAsiaNews.Com believes the worst is behind for the pharma major with this USFDA boost, a USD 3.4 billion opportunity.
 Money Control2 months ago Ranbaxy stock up 50% post deal with Sun Pharma  Economic Times1 month ago U.S FDA Ban Ranbaxy: Stocks Dip!  Silicon India1 month ago Ranbaxy, Sun Pharma up 6-8% on US FDA nod; analysts bullish  Moneycontrol.com2 months ago
Securities Technology Monitor

Rascal Flatts Joins the Thousands of People Who Choose Nexium® 24HR Every Day for Their Frequent Heartburn

Join Rascal Flatts Today and Choose Nexium 24HR - Satisfaction Guaranteed NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) announced today that the members of Rascal Flatts, the most-awarded country music band of the past decade, are among the ...
 Nasdaq3 weeks ago INTERVIEW: Rascal Flatts on finding their new EDM-tinged sound  She Knows3 weeks ago AstraZeneca PLC Touts 2nd Quarter Results After Fending Off Pfizer Inc., CEO And Investors Rejoice  BioSpace4 weeks ago Pfizer Releases 2Q 2014 Results  Individual.com4 weeks ago

Nexium Petroleum CEO Urges CDA Graduates to Remain Focused

Monrovia — The Chief Executive Officer (CEO) of the Nexium Petroleum Limited in Liberia, has urged graduates of the Child Development Academy (CDA) high school to have confidence in their decisions and capabilities, while reminding them to nurture ...
 AllAfrica.com2 months ago

Another Nexium patent case closed

 Pharma In Focus1 week ago
FDA News

AstraZeneca Sues Zydus Cadila Over Generic Nexium Bid

AstraZeneca has sued India-based generics firm Zydus Cadila to block its bid for a version of the brand manufacturer's acid-reflux drug Nexium. The lawsuit, filed July 31 in the U.S. District Court for the District of New Jersey, claims ...
 FDA News3 weeks ago AstraZeneca Has 30% Upside As A Takeover Candidate  Seeking Alpha3 weeks ago AstraZeneca results to get lift from bid foe Pfizer  4 Traders1 month ago

AstraZeneca lifts annual guidance as Q2 sales rise 4 percent, boosted by Nexium payment

AstraZeneca said Thursday that sales in the second quarter rose 4 percent year-over-year to $6.5 billion, topping analyst estimates of $6.3 billion, lifted by a $200-million payment from Pfizer for rights to an over-the-counter version of Nexium.
 FirstWord Pharma1 month ago AstraZeneca Ups '14 Outlook  FOXBusiness.com1 month ago AstraZeneca beats expectations and raises forecasts after shooing off Pfizer  MedCity News1 month ago AstraZeneca Raises 2014 Guidance  Bidness Etc1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less